摘要
Abstract
Objective To investigate the efficacy and adverse reactions of thalidomide and paclitaxel and cisplatin (TP) in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC).Methods Select the elderly (≥60 years) 62 patients with advanced NSCLC , all cases were previously untreated patients were randomly divided into two groups, the treatment group of 31 patients received TP regimen , starting on the first day of chemotherapy oral thalidomide 100 mg/d, if the patient can tolerate , one week after the dosage to 200 mg/d,21 d as a cycle, continuous oral three months;con-trol group of 31 patients received TP regimen .Each patient received at least two cycles of treatment .Results Effective rate in treatment group was 43.3%, in the control group was 38.7%( P >0.05);disease control rate was 86.7%and 64.5%, the difference was statistically significant ( P <0.05);treatment group improved KPS score rate , the rate of increase in appetite and weight gain rate than the control group ( P <0.05).The median progression-free survival ( PFS) treatment group was 7.97 months in the control group was 5.94 months;median overall survival (OS) treatment group 12.71 months in the control group 11.23 months, the treatment group than the control group extended ( P <0.05).Adverse reactions were I and II Class alopecia , leukopenia , muscle and joint pain , and nausea and vomiting , III-IV grade low incidence , two groups in addition to nausea and vomiting were significantly different ( P <0.05), the rest had no statistically significant ( P >0.05).No thalid-omide-related hemorrhage , thrombosis and III -IV grade drowsiness , constipation and other adverse reactions .Conclusion The TP regimen of thalidomide treatment of advanced NSCLC , improve the patient's disease control rate , quality of life and prolong survival, no significant adverse reactions , safe, worthy of clinical application .关键词
沙利度胺/紫杉醇/顺铂/肺癌,非小细胞/老年人Key words
Thalidomide/Paclitaxel/Cisplatin/Lung cancer,non-small cell/Elderly
